Risikovurdering i 2. trimester vedr. Downs syndrom - DFMS
Risikovurdering i 2. trimester vedr. Downs syndrom - DFMS
Risikovurdering i 2. trimester vedr. Downs syndrom - DFMS
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Referencer:<br />
Cuckle, H., Wald, N. and Lindenbaum, R. (1984): Maternal serum alpha-fetoprotein measurement:<br />
a screening test for Down´s <strong>syndrom</strong>e. Lancet 1, 926-929<br />
Canick JA, Knight GJ, Palomaki GE, et al.Low second <strong>trimester</strong> maternal serumunconjungates<br />
oestriol in pregnancies with Down´s <strong>syndrom</strong>e. Br J Obstet Gynaecol 1988;95:330-3<br />
Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in<br />
pregnancies with fetal chromosome abnormalities. Prenat Diagn. 1987;7:623-30<br />
Van Lith JM, Pratt JJ, Beekhuis JR, et al Second-<strong>trimester</strong> maternal serum immunoreactive inhibin<br />
as a marker for fetal Down´s <strong>syndrom</strong>e. Prenat. Diagn. 1992;12(10):801-6<br />
Wallace EM. Grant VE, Swanston IA, et al. Evaluation of maternal serum dimeric inhibin A as a<br />
first-<strong>trimester</strong> marker of Down´s <strong>syndrom</strong>e. Prenat diagn 1995;15(4):359-62<br />
Cuckle H., Benn P. and Wright D. (2005) Down <strong>syndrom</strong>e screening in the first and/or second<br />
<strong>trimester</strong>: Model predicted performance using meta-analysis parameters. Seminars in perinatology<br />
29, 215-8<br />
SURUSS in perspective<br />
FASTER<br />
Cuckle H, Benn PA. Multi-marker maternal serum screening for chromosome abnormalities. In:<br />
Milunsky JA, editors. Genetic Disorders and the fetus 6 th edition Chichester: Wiley-Blachwell; 2010.<br />
p 771-818<br />
Shamshirsaz, A. A., Benn P. and Egan J.F.X. (2010): The role of Second Trimester Serum<br />
Screening in the Post – First – Trimester Screening Era. Clin Lab Med 30, 667-676<br />
Wald NJ, Rodeck C, Hackshaw AK, et al. (2003) First and second <strong>trimester</strong> antenatal screening for<br />
Down´s <strong>syndrom</strong>e: the result of the Serum, Urine and Ultrasound Screening study (SURUSS).<br />
Health Technol Asess 2003;7:1-77<br />
Malone FD, Canick JA, Ball RH, et al. First and second <strong>trimester</strong> Evaluation of Risk for Fetal<br />
Aneuploidy (FASTER): Principal results of the NICHD multicenter Down <strong>syndrom</strong>e screening<br />
study. N Engl. J Med. 2005;353: 2001-11<br />
Sammenfattende <strong>vedr</strong>. biokemiske markører:<br />
Der udføres færre og færre biokemiske test for DS i <strong>2.</strong> <strong>trimester</strong> i Danmark, da der oftest vælges 1.<br />
<strong>trimester</strong> risikoberegning eller ultralydsbaseret risikovurdering. Undersøgelserne er dog endnu<br />
aktuelle i udvalgte tilfælde, og i øjeblikket er det for praktiske forhold kun tripletest, der udføres.<br />
Denne kan foretages på Seruminstituttet. I fremtiden vil Inhibin måske få en plads.<br />
40